Demant A/S Unsponsored ADR (OTCMKTS:WILYY) Sees Significant Growth in Short Interest

Demant A/S Unsponsored ADR (OTCMKTS:WILYY) was the recipient of a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 2,028 shares, an increase of 2,231.0% from the May 14th total of 87 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 752 shares, the days-to-cover ratio is presently 2.7 days.

Demant A/S Stock Up 1.8%

Shares of WILYY stock traded up $0.35 during trading on Tuesday, reaching $20.05. The company had a trading volume of 318 shares, compared to its average volume of 495. The firm’s 50 day simple moving average is $17.06 and its two-hundred day simple moving average is $16.10. Demant A/S has a one year low of $13.45 and a one year high of $21.93. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 1.65.

Analysts Set New Price Targets

Separately, Jefferies Financial Group upgraded shares of Demant A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 18th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Demant A/S currently has a consensus rating of “Buy”.

Demant A/S Company Profile

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.